Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Greenwich LifeSciences (GLSI – Research Report) ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

NASDAQ:GLSI opened at $12.38 on Friday. Greenwich LifeSciences has a 52 week low of $9.91 and a 52 week high of $21.44. The firm has a market capitalization of $162.80 million, a PE ratio of -15. ...

(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, on Wednesday, announced that its application seeking expansion of its FLAMINGO-01 clinical trial in ...

Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01.